Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
- Maertens, Johan
- Raad, Issam I
- Marr, Kieren A
- Patterson, Thomas F
- Kontoyiannis, Dimitrios P
- Cornely, Oliver A
- Bow, Eric J
- Rahav, Galia
- Neofytos, Dionysios
- Aoun, Mickael
- Baddley, John W
- Giladi, Michael
- Heinz, Werner J
- Herbrecht, Raoul
- Hope, William
- Karthaus, Meinolf
- Lee, Dong-Gun
- Lortholary, Olivier
- Morrison, Vicki A
- Oren, Ilana
- Selleslag, Dominik
- Shoham, Shmuel
- Thompson, George R
- Lee, Misun
- Maher, Rochelle M
- Schmitt-Hoffmann, Anne-Hortense
- Zeiher, Bernhardt
- Ullmann, Andrew J
Publication date
February 2016
DOI Publisher
The Lancet Publishing Group ISSN
0140-6736 Journal
1474-547xAbstract
Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease.status: publishe
Add to ORKG